PMID- 30242748
OWN - NLM
STAT- MEDLINE
DCOM- 20190814
LR  - 20200225
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 27
IP  - 1
DP  - 2019 Feb
TI  - IL-1beta, IL-17A and combined phototherapy predicts higher while previous systemic 
      biologic treatment predicts lower treatment response to etanercept in psoriasis 
      patients.
PG  - 57-66
LID - 10.1007/s10787-018-0530-9 [doi]
AB  - BACKGROUND: This study aimed to explore the correlation of circulating 
      inflammatory cytokines' levels with treatment response to etanercept (ETN) 
      treatment in psoriasis patients. METHODS: 97 moderate-to-severe plaque-psoriasis 
      patients were continuously recruited in this prospective cohort study, and all 
      patients received ETN treatment. Serum samples were collected before and at 
      6 months (M6) after treatment, and nine inflammatory cytokines expressions were 
      detected by enzyme-linked immuno sorbent assay. Psoriasis Area and Severity Index 
      (PASI) score was evaluated at baseline (M0), 1 month (M1), 3 months (M3) and M6 
      after treatment, and the corresponding PASI 75/90 responses' rates were 
      calculated. RESULTS: Tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, 
      IL-6, IL-12, IL-17A, IL-22, IL-23, and IL-32 levels were reduced, while IL-10 
      level was elevated at M6 after ETN treatment compared to baseline. PASI 75/90 
      responses' rates to ETN were 69.1 and 38.1% at M6, respectively. IL-1beta and IL-17A 
      levels were elevated in PASI 75-response patients compared to PASI 75 
      non-response patients, while IL-17A level was also increased in PASI 90-response 
      patients compared to PASI 90 non-response patients. Multivariate logistic 
      regression revealed that IL-1beta, IL-17A and combined phototherapy during study 
      predicted higher, while previous systemic biologic treatment predicted lower PASI 
      75 response to ETN independently. In addition, IL-17A independently predicted 
      higher PASI 90 response to ETN as well. CONCLUSIONS: IL-1beta, IL-17A, and combined 
      phototherapy predicts higher while previous systemic biologic treatment predicts 
      lower treatment response to ETN independently in psoriasis patients.
FAU - Liu, Yufang
AU  - Liu Y
AD  - Department of Dermatology, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 
      442000, China.
FAU - Qin, Guifang
AU  - Qin G
AD  - Department of Dermatology, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 
      442000, China.
FAU - Meng, Zudong
AU  - Meng Z
AUID- ORCID: 0000-0002-2158-6368
AD  - Department of Dermatology, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 
      442000, China. mengzudong3320@126.com.
FAU - Du, Tianping
AU  - Du T
AD  - Department of Neurosurgery, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, Shiyan, China.
FAU - Wang, Xiaolan
AU  - Wang X
AD  - Department of Dermatology, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 
      442000, China.
FAU - Tang, Yong
AU  - Tang Y
AD  - Department of Rehabilitation, Sinopharm Dong Feng General Hospital, The 
      Affiliated Dong Feng Hospital, Hubei University of Medicine, Shiyan, China.
FAU - Cao, Jingjing
AU  - Cao J
AD  - Department of Dermatology, The People's Hospital of Shiyan, The Affiliated 
      People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 
      442000, China.
LA  - eng
PT  - Journal Article
DEP - 20180921
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (IL17A protein, human)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
MH  - Etanercept/*therapeutic use
MH  - Female
MH  - Humans
MH  - Interleukin-17/*metabolism
MH  - Interleukin-1beta/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Phototherapy/methods
MH  - Prospective Studies
MH  - Psoriasis/*drug therapy/*metabolism
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Inflammatory cytokines
OT  - PASI score
OT  - Psoriasis
OT  - Treatment response
EDAT- 2018/09/23 06:00
MHDA- 2019/08/15 06:00
CRDT- 2018/09/23 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/09/07 00:00 [accepted]
PHST- 2018/09/23 06:00 [pubmed]
PHST- 2019/08/15 06:00 [medline]
PHST- 2018/09/23 06:00 [entrez]
AID - 10.1007/s10787-018-0530-9 [pii]
AID - 10.1007/s10787-018-0530-9 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2019 Feb;27(1):57-66. doi: 10.1007/s10787-018-0530-9. Epub 
      2018 Sep 21.